Robert Weinstein

Insider Reports History

Reporting-owner location: Las Vegas, NV
Latest reporting-owner signature: /s/ Robert Weinstein
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert Weinstein

Form 4 holding Chief Financial Officer

TAO Synergies Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 16,574
Estimated value: $119,830
Report date: 17 Oct 2025
Price: $7.23
Ownership: Direct

Form 4 holding Director

XWELL, Inc.

Security class: Common Stock
Shares / value: 215,231
Estimated value: $101,158
Report date: 27 Feb 2026
Price: $0.4700
Ownership: Direct

Form 4 holding Director

PharmaCyte Biotech, Inc.

Security class: Common Stock
Shares / value: 41,250
Estimated value: $42,075
Report date: 12 Dec 2025
Price: $1.02
Ownership: Direct

Form 4 holding Director

PharmaCyte Biotech, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 119,170
Estimated value
Report date: 31 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

XWELL, Inc.

Security class: Employee stock option (right to buy)
Shares / value: 117,886
Estimated value
Report date: 02 Jun 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Financial Officer

TAO Synergies Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 30,000
Estimated value
Report date: 18 May 2026
Price
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount

Form 4 holding Chief Financial Officer

TAO Synergies Inc.

Security class: Employee Stock Option (right to buy)
Shares / value: 7,000
Estimated value
Report date: 06 Aug 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Robert Weinstein

4 TAOX

TAO Synergies Inc.

Report period: 18 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 May 2026, 18:43
Role: Chief Financial Officer
Next action: Open filing details

4 PMCB

PharmaCyte Biotech, Inc.

Report period: 31 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Apr 2026, 18:17
Role: Director
Next action: Open filing details

4 XWEL

XWELL, Inc.

Report period: 27 Feb 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Mar 2026, 19:45
Role: Director
Next action: Open filing details

4 SNPX

TAO Synergies Inc.

Report period: 06 Aug 2025
Transactions: 3
Transaction value: -$28,920
Accepted by SEC: 17 Oct 2025, 17:14
Role: Chief Financial Officer
Next action: Open filing details

4 SNPX

TAO Synergies Inc.

Report period: 30 Jun 2025
Transactions: 2
Transaction value: -$48,387
Accepted by SEC: 02 Jul 2025, 16:06
Role: Chief Financial Officer
Next action: Open filing details

4 XWEL

XWELL, Inc.

Report period: 02 Jun 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Jun 2025, 08:01
Role: Director
Next action: Open filing details

4 PMCB

PharmaCyte Biotech, Inc.

Report period: 25 Apr 2025
Transactions: 3
Transaction value: -$34,425
Accepted by SEC: 12 Dec 2025, 17:08
Role: Director
Next action: Open filing details

4 XWEL

XWELL, Inc.

Report period: 15 Nov 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 18 Nov 2024, 18:37
Role: Director
Next action: Open filing details

4 PMCB

PharmaCyte Biotech, Inc.

Report period: 30 Apr 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jul 2024, 16:59
Role: Director
Next action: Open filing details

4 PMCB

PharmaCyte Biotech, Inc.

Report period: 20 Nov 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Nov 2023, 17:02
Role: Director
Next action: Open filing details

4 XWEL

XWELL, Inc.

Report period: 30 May 2023
Transactions: 1
Transaction value: +$6,175
Accepted by SEC: 31 May 2023, 08:32
Role: Director
Next action: Open filing details

3 OBLG

Oblong, Inc.

Report period: 29 May 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 01 Jun 2023, 16:05
Role: Director
Next action: Open filing details

4 XWEL

XWELL, Inc.

Report period: 26 May 2023
Transactions: 1
Transaction value: +$6,250
Accepted by SEC: 30 May 2023, 08:34
Role: Director
Next action: Open filing details

4/A XWEL

XWELL, Inc.

Report period: 05 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Jan 2023, 20:37
Role: Director
Next action: Open filing details

4 SNPX

Synaptogenix, Inc.

Report period: 16 Dec 2022
Transactions: 1
Transaction value: -$31,641
Accepted by SEC: 20 Dec 2022, 19:02
Role: Chief Financial Officer
Next action: Open filing details

4/A SNPX

Synaptogenix, Inc.

Report period: 15 Nov 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Dec 2022, 18:54
Role: Chief Financial Officer
Next action: Open filing details

3 PMCB

PharmaCyte Biotech, Inc.

Report period: 14 Nov 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 16 Nov 2022, 15:12
Role: Director
Next action: Open filing details

4 XWEL

XpresSpa Group, Inc.

Report period: 20 Apr 2022
Transactions: 1
Transaction value: -$47,700
Accepted by SEC: 22 Apr 2022, 19:59
Role: Director
Next action: Open filing details

4 XWEL

XpresSpa Group, Inc.

Report period: 26 Jan 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 31 Jan 2022, 19:19
Role: Director
Next action: Open filing details

4 XWEL

XpresSpa Group, Inc.

Report period: 19 Jan 2022
Transactions: 1
Transaction value: -$70,236
Accepted by SEC: 21 Jan 2022, 16:08
Role: Director
Next action: Open filing details

4 XWEL

XpresSpa Group, Inc.

Report period: 20 Oct 2021
Transactions: 1
Transaction value: -$90,210
Accepted by SEC: 22 Oct 2021, 16:15
Role: Director
Next action: Open filing details

4 XWEL

XpresSpa Group, Inc.

Report period: 29 Jul 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Jul 2021, 17:22
Role: Director
Next action: Open filing details

4 SNPX

Synaptogenix, Inc.

Report period: 13 Jul 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Jul 2021, 18:06
Role: Chief Financial Officer
Next action: Open filing details

3 SNPX

Synaptogenix, Inc.

Report period: 04 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 14 Jun 2021, 20:16
Role: Chief Financial Officer
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .